2008 Portfolio News
News from the portfolios of HBM BioVentures and HBM BioCapital
Biomarin's Kuvan receives marketing approval in the EU
Broncus Technologies Secures 38$ Million in fundind round led by Ares Life Sciences
Biovitrum extends ReFacto supply agreement with Wyeth until Dec. 31, 2015
Sale of private portfolio company Panomics
Brahms announces new blood test better predicts heart failure outcomes in emergency setting
Paratek reports positive phase 2 clinical data on antibiotic PTK 0796
Mpex Pharmaceuticals presents new data on MP-376 in Cystic Fibrosis
Probiodrug's new Alzheimer's treatment paradigm published in Nature Medicine
Takeover of public portfolio company CryoCath Technologies
Biovitrum to acquire Kepivance, Stemgen and exclusively license Kineret from Amgen
Basilea's Toctino (alitretinoin) receives first national marketing authorization in the UK
BRAHMS AG: Substantial success in the improvement of diagnosis of patients suffering from shortness of breath
Anthera Pharmaceuticals initiates FRANCIS in patients with acute coronary syndrome
Anthera Pharmaceuticals completes $19 million financing
ESBATech raises additional CHF 23M (USD 22M), extending Series B Venture Financing
Onyx' Nexavar approved for liver cancer in China
PTC Therapeutics closes significant cooperation agreement with Genzyme, receives $ 100 million upfront payment
FDA grants conditional approval to Interventional Spine's PercuDyn system IDE application
Kolltan Pharmaceuticals closes $ 10 million series B related financing
Successful sale of BRAHMS in an all-cash transaction to Thermo Fisher Scientific
